• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nu Skin Enterprises Reports First Quarter Results

    5/8/24 4:06:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care
    Get the next $NUS alert in real time by email

    Nu Skin Enterprises Inc. (NYSE:NUS) today announced first quarter results in line with guidance.

    Executive Summary

    Q1 2024 vs. Prior-year Quarter

     

    Revenue

    $417.3 million; (13.3)%

    • (3.8)% FX impact or $(18.2) million
    • Rhyz revenue $62.5 million; 57.5%

    Earnings Per Share (EPS)

    $(0.01) or $0.09 excluding restructuring charges compared to $0.23 or $0.37 excluding restructuring charges

    Customers

    875,261; (19)%

    Paid Affiliates

    154,171; (30)% or (14)% excluding an adjustment to eligibility requirements

    Sales Leaders

    38,609; (12)%

    "Our first quarter revenue came in at the mid-point of our guidance, negatively impacted more than anticipated by foreign currency headwinds, while our cost management efforts helped us post earnings per share in the upper half of our guide," said Ryan Napierski, Nu Skin president and CEO. "We are continuing our business transformation efforts and making progress in developing our integrated beauty, wellness and lifestyle ecosystem. During the quarter, we again drove strong gains in our Rhyz business, growing nearly 60% year-over-year. In our Nu Skin core business, the macro-economic environment impacted affiliate and customer growth around the globe, but we are encouraged by the performance of our ageLOC WellSpa iO, RenuSpa iO and TRMe launches.

    "At our annual top sales leader event, we aligned around the upcoming preview of our new MYND360 cognitive health line and saw healthy energy for the opening of India next year. We also introduced some new early affiliate rewards and top leader incentives to help drive customer acquisition and business growth. While we continue to navigate the challenges of a business transformation amid these disruptive times, we continue to evolve our strategy for both our Nu Skin and Rhyz businesses and remain focused on generating long-term growth and returning value to shareholders."

    Q1 2024 Year-over-year Operating Results

     

    Revenue

    $417.3 million compared to $481.5 million

    • (3.8)% FX impact or $(18.2) million
    • Rhyz revenue $62.5 million; 57.5%

    Gross Margin

    70.5% compared to 72.3%

    • Nu Skin business was 76.9% compared to 76.4%

    Selling Expenses

    36.8% compared to 39.1%

    • Nu Skin business was 41.7% compared to 41.7%

    G&A Expenses

    29.9% compared to 27.8%

    Operating Margin

    2.1% or 3.8% excluding restructuring charges compared to 3.3% or 5.4% excluding restructuring charges

    Interest Expense

    $7.3 million compared to $4.9 million

    Other Income/(Expense)

    $(0.4) million compared to $3.4 million

    Income Tax Rate

    148.4% or 48.5% excluding restructuring charges compared to 22.0%

    EPS

    $(0.01) or $0.09 excluding restructuring charges compared to $0.23 or $0.37 excluding restructuring charges 

    Stockholder Value

     

    Dividend Payments

    $3.0 million

    Stock Repurchases

    $0.0 million

    • $162.4 million remaining in authorization

    Q2 and Full-year 2024 Outlook

     

    Q2 2024 Revenue

    $420 to $455 million; (16)% to (9)%

    • Approximately (4) to (3)% FX impact

    Q2 2024 EPS

    $0.01 to $0.10 or $0.10 to $0.20 non-GAAP

    2024 Revenue

    $1.73 to $1.87 billion; (12)% to (5)%

    • Approximately (3) to (2)% FX impact

    2024 EPS

    $0.77 to $1.16 or $0.95 to $1.35 non-GAAP

    "We continue to implement strategic measures to refine our cost structure in line with business performance and strengthen our financial outlook," said James D. Thomas, chief financial officer. "The additional efficiencies garnered from our cost-saving initiatives underscore our dedication to boosting productivity. We remain vigilant in scrutinizing all facets of our operations and prioritizing initiatives to drive revenue, amplify margins and secure our financial position. Although negative foreign currency impacted our results more than initially expected and will likely continue to do so, we are keeping our 2024 guidance numbers intact. For the second quarter, we project sequential improvement with revenue of $420 to $455 million, assuming an increased foreign currency impact, with reported earnings per share of $0.01 to $0.10 or $0.10 to $0.20 excluding restructuring charges."

    Conference Call

    The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available on the same page through May 22, 2024.

    About Nu Skin Enterprises Inc.

    The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which includes an award-winning line of beauty device systems. Formed in 2018, Rhyz is a synergistic ecosystem of consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.

    Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the macro environment and the company's performance, growth and growth opportunities, shareholder value, productivity, product previews and launches, transformation, evolution, investments, initiatives, digital tools and initiatives, and new market expansion; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, future dividends, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "anticipate," "accelerate," "project," "vision," "continue," "outlook," "guidance," "improve," "will," "would," "could," "may," "might," the negative of these words and other similar words.

    The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

    • any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a sustained basis;
    • risk that direct selling laws and regulations in any of the company's markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company's business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;
    • economic conditions and events globally;
    • competitive pressures in the company's markets;
    • risk that epidemics, including COVID-19 and related disruptions, or other crises could negatively impact our business;
    • adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
    • political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;
    • uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;
    • risk of foreign-currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
    • uncertainties regarding the future financial performance of the businesses the company has acquired;
    • risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
    • regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements; and
    • the company's future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company's products imported into the company's markets outside of the United States, and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets.

    The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

    Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company's performance. It is calculated by translating the current period's revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period's revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company's revenue from period to period.

    Earnings per share, operating margin and income tax rate, each excluding restructuring and/or impairment charges, also are non-GAAP financial measures. Restructuring and impairment charges are not part of the ongoing operations of our underlying business. The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these charges facilitates period-to-period comparisons of the company's performance. Please see the reconciliations of these items to our earnings per share, operating margin and income tax rate calculated under GAAP, below.

    The following table sets forth revenue for the three-month periods ended March 31, 2024, and 2023 for each of our reportable segments (U.S. dollars in thousands):

    Three Months Ended

    March 31,

     

     

    Constant-

    Currency

     

    2024

     

    2023

     

    Change

     

    Change

    Nu Skin

    Americas

    $

    75,031

     

    $

    101,157

     

     

    (25.8)%

     

    (20.1)%

    Mainland China

     

    61,067

     

     

    67,976

     

     

    (10.2)%

     

    (6.1)%

    Southeast Asia/Pacific

     

    60,065

     

     

    67,810

     

     

    (11.4)%

     

    (8.1)%

    Japan

     

    44,236

     

     

    52,606

     

     

    (15.9)%

     

     

    (5.6)%

    Europa & Africa

     

    42,273

     

     

    47,444

     

     

    (10.9)%

     

    (11.8)%

    South Korea

     

    40,963

     

     

    70,324

     

     

    (41.8)%

     

     

    (39.3)%

    Hong Kong/Taiwan

     

    30,466

     

     

    34,548

     

     

    (11.8)%

     

    (9.8)%

    Nu Skin other

     

    672

     

     

    (115)

     

     

    684.3%

     

     

    684.3%

    Total Nu Skin

    354,773

    441,750

    (19.7)%

    (15.6)%

    Rhyz Investments

    Manufacturing

    50,302

    35,767

    40.6%

    40.6%

    Rhyz other

    12,231

    3,945

    210.0%

    210.0%

    Total Rhyz Investments

    62,533

    39,712

    57.5%

    57.5%

    Total

    $

    417,306

     

    $

    481,462

     

     

    (13.3)%

     

    (9.5)%

    The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended March 31, 2024, and 2023:

    Three Months Ended

    March 31,

     

     

    2024

     

    2023

     

    Change

    Customers

     

     

     

     

     

     

     

    Americas

     

    199,399

    266,378

    (25)%

    Mainland China

     

    162,239

    217,101

    (25)%

    Southeast Asia/Pacific

     

    93,411

    117,266

    (20)%

    Japan

     

    108,808

    115,161

     

    (6)%

    Europe & Africa

     

    163,481

    190,313

    (14)%

    South Korea

     

    100,230

    120,907

    (17)%

    Hong Kong/Taiwan

     

    47,693

    56,410

    (15)%

    Total Customers

    875,261

    1,083,536

    (19)%

    Paid Affiliates

     

     

     

     

     

     

     

    Americas

     

    29,081

    38,707

    (25)%

    Mainland China

     

    24,405

    24,522

    —

    Southeast Asia/Pacific

     

    29,778

    36,431

    (18)%

    Japan(1)

     

    21,679

    37,155

    (42)%

    Europe & Africa(1)

     

    18,313

    27,654

    (34)%

    South Korea(1)

     

    20,594

    40,599

    (49)%

    Hong Kong/Taiwan(1)

     

    10,321

    16,286

    (37)%

    Total Paid Affiliates

    154,171

    221,354

    (30)%

    Sales Leaders

     

     

     

     

     

     

     

    Americas

     

    6,616

    8,242

    (20)%

    Mainland China

    9,600

    10,034

    (4)%

    Southeast Asia/Pacific

     

    5,570

    6,337

    (12)%

    Japan

     

    6,385

    5,688

    12%

    Europe & Africa

     

    3,715

    4,524

    (18)%

    South Korea

     

    4,122

    6,242

    (34)%

    Hong Kong/Taiwan

     

    2,601

    2,688

    (3)%

    Total Sales Leaders

    38,609

    43,755

    (12)%

    (1)

    The March 31, 2024, number is affected by a change in eligibility requirements for receiving certain rewards within our compensation structure. We plan to implement these changes in additional segments over the next several quarters. We estimate the change in eligibility requirements resulted in a reduction of approximately 14,000; 5,000; 13,000 and 3,000 for Japan, Europe & Africa, South Korea and Hong Kong/Taiwan, respectively.

    • "Customers" are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.
    • "Paid Affiliates" are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as "Brand Affiliates" because their primary role is to promote our brand and products through their personal social networks.
    • "Sales Leaders" are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the quarter.
     

    NU SKIN ENTERPRISES, INC.

    Consolidated Statements of Income (Unaudited)

    (U.S. dollars in thousands, except per share amounts)

     

    Three Months Ended

    March 31,

     

    2024

     

    2023

    Revenue

    $

    417,306

     

    $

    481,462

    Cost of sales

     

    123,242

     

     

    133,588

    Gross profit

     

    294,064

     

     

    347,874

     

     

     

     

     

     

    Operating expenses:

     

     

     

     

     

    Selling expenses

     

    153,542

     

     

    188,124

    General and administrative expenses

     

    124,566

     

     

    133,899

    Restructuring and impairment expenses

     

    7,134

     

     

    9,787

    Total operating expenses

     

    285,242

     

     

    331,810

     

     

     

     

     

     

    Operating income

     

    8,822

     

     

    16,064

    Interest expense

     

    7,325

     

     

    4,888

    Other income (expense), net

     

    (396)

     

     

    3,412

     

     

     

     

     

     

    Income before provision for income taxes

     

    1,101

     

     

    14,588

    Provision for income taxes

     

    1,634

     

     

    3,212

     

     

     

     

     

     

    Net (loss) income

    $

    (533)

     

    $

    11,376

     

     

     

     

     

     

    Net (loss) income per share:

     

     

     

     

     

    Basic

    $

    (0.01)

     

    $

    0.23

    Diluted

    $

    (0.01)

     

    $

    0.23

     

     

     

     

     

     

    Weighted-average common shares outstanding (000s):

     

     

     

     

     

    Basic

     

    49,538

     

     

    49,644

    Diluted

     

    49,538

     

     

    50,058

     

    NU SKIN ENTERPRISES, INC.

    Consolidated Balance Sheets (Unaudited)

    (U.S. dollars in thousands)

     

     

     

     

     

    March 31,

    2024

     

    December 31,

    2023

    ASSETS

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    212,532

     

    $

    256,057

    Current investments

     

    8,674

     

     

    11,759

    Accounts receivable, net

     

    67,041

     

     

    72,879

    Inventories, net

     

    265,100

     

     

    279,978

    Prepaid expenses and other

     

    93,913

     

     

    81,198

    Total current assets

     

    647,260

     

     

    701,871

     

     

     

     

     

     

    Property and equipment, net

     

    422,818

     

     

    432,965

    Operating lease right-of-use assets

    93,092

    90,107

    Goodwill

     

    230,768

     

     

    230,768

    Other intangible assets, net

     

    101,933

     

     

    105,309

    Other assets

     

    246,044

     

     

    245,443

    Total assets

    $

    1,741,915

     

    $

    1,806,463

     

     

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

     

     

    Current liabilities:

     

     

     

     

     

    Accounts payable

    $

    32,237

     

    $

    43,505

    Accrued expenses

     

    247,068

     

     

    260,366

    Current portion of long-term debt

     

    30,000

     

     

    25,000

    Total current liabilities

     

    309,305

     

     

    328,871

     

    Operating lease liabilities

     

    74,198

     

     

    70,943

    Long-term debt

     

    453,183

     

     

    478,040

    Other liabilities

     

    95,023

     

     

    106,641

    Total liabilities

     

    931,709

     

     

    984,495

     

     

     

     

     

     

    Commitments and contingencies

     

     

     

     

     

     

     

     

     

     

     

    Stockholders' equity:

     

     

     

     

     

    Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued

     

    91

     

     

    91

    Additional paid-in capital

     

    618,706

     

     

    621,853

    Treasury stock, at cost – 40.9 million and 41.1 million shares

     

    (1,564,942)

     

     

    (1,570,440)

    Accumulated other comprehensive loss

     

    (110,607)

     

     

    (100,006)

    Retained earnings

     

    1,866,958

     

     

    1,870,470

    Total stockholders' equity

     

    810,206

     

     

    821,968

    Total liabilities and stockholders' equity

    $

    1,741,915

     

    $

    1,806,463

     

    NU SKIN ENTERPRISES, INC.

    Reconciliation of Operating Margin Excluding Impact of Restructuring to GAAP Operating Margin

    (in thousands, except for per share amounts)

     

     

     

     

     

     

     

     

     

    Three months ended

    March 31,

     

     

    2024

     

    2023

    Operating Income

     

    $

    8,822

     

    $

    16,064

    Impact of restructuring and impairment:

     

     

     

     

     

     

    Restructuring and impairment

     

     

    7,134

     

     

    9,787

    Adjusted operating income

     

    $

    15,956

     

    $

    25,851

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Operating margin

     

     

    2.1%

     

     

    3.3%

    Operating margin, excluding restructuring impact

     

     

    3.8%

     

     

    5.4%

     

     

     

     

     

     

     

    Revenue

     

    $

    417,306

     

    $

    481,462

     

    NU SKIN ENTERPRISES, INC.

    Reconciliation of Effective Tax Rate Excluding Impact of Restructuring to GAAP Effective Tax Rate

    (in thousands, except for per share amounts)

     

     

     

     

     

     

     

     

     

    Three months ended

    March 31,

     

     

    2024

     

    2023

    Provision (benefit) for income taxes

     

    $

    1,634

     

    $

    3,212

    Impact of restructuring on provision for income taxes

     

     

    2,356

     

     

    2,593

    Provision for income taxes, excluding impact of restructuring

     

    $

    3,990

     

    $

    5,805

     

     

     

     

     

     

     

    Income before provision for income taxes

     

     

    1,101

     

     

    14,588

    Impact of restructuring and impairment expense:

     

     

     

     

     

     

    Restructuring and impairment

     

     

    7,134

     

     

    9,787

    Income before provision for income taxes, excluding impact of restructuring

     

    $

    8,235

     

    $

    24,375

     

     

     

     

     

     

     

    Effective tax rate

     

     

    148.4%

     

     

    22.0%

    Effective tax rate, excluding restructuring impact

     

     

    48.5%

     

     

    23.8%

     

    NU SKIN ENTERPRISES, INC.

    Reconciliation of Earnings Per Share Excluding Impact of Restructuring to GAAP Earnings Per Share

    (in thousands, except for per share amounts)

     

     

     

     

     

     

     

     

     

    Three months ended

    March 31,

     

     

    2024

     

    2023

    Net (loss) income

     

    $

    (533)

     

    $

    11,376

    Impact of restructuring and impairment expense:

     

     

     

     

     

     

    Restructuring and impairment

     

     

    7,134

     

     

    9,787

    Tax impact

     

     

    (2,356)

     

     

    (2,593)

    Adjusted net income

     

    $

    4,245

     

    $

    18,570

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Diluted earnings per share

     

    $

    (0.01)

     

    $

    0.23

    Diluted earnings per share, excluding restructuring impact

     

    $

    0.09

     

    $

    0.37

     

     

     

     

     

     

     

    Weighted-average common shares outstanding (000)

     

     

    49,538

     

     

    50,058

     

    NU SKIN ENTERPRISES, INC.

    Reconciliation of Earnings Per Share Excluding Impact of Restructuring to GAAP Earnings Per Share

     

     

     

    Three months ended

    June 30,

     

    Year ended

    December 31,

     

     

    2024 - Low-end

     

    2024 High-end

     

    2024 - Low-end

     

    2024 High-end

    Earnings Per Share

     

    $

    0.01

     

    $

    0.10

     

    $

    0.77

     

    $

    1.16

    Impact of restructuring expense:

     

     

     

     

     

     

     

     

     

     

     

     

    Restructuring

     

     

    0.15

     

     

    0.15

     

     

    0.29

     

     

    0.29

    Tax impact

     

     

    (0.06)

     

     

    (0.05)

     

     

    (0.11)

     

     

    (0.10)

    Adjusted EPS

     

    $

    0.10

     

    $

    0.20

     

    $

    0.95

     

    $

    1.35

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240508284158/en/

    Get the next $NUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUS

    DatePrice TargetRatingAnalyst
    1/31/2023$43.00 → $39.00Buy → Hold
    Jefferies
    2/17/2022$47.00 → $50.00Neutral
    DA Davidson
    11/24/2021$43.00 → $49.00Neutral
    Citigroup
    10/6/2021$61.00 → $47.00Neutral
    DA Davidson
    More analyst ratings

    $NUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and General Counsel Clark Chayce David covered exercise/tax liability with 9,049 shares, decreasing direct ownership by 4% to 224,091 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    12/23/25 4:50:21 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Director Woodbury Edwina D was granted 10 shares, increasing direct ownership by 0.02% to 42,979 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    12/11/25 4:44:37 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Chief Product Officer Hatchett Steven Keith bought $52,855 worth of shares (5,500 units at $9.61), increasing direct ownership by 3% to 167,565 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    11/12/25 4:32:45 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dr. Joseph Chang Launches Update to Bestselling Book "The Aging Myth" With 15 More Years of Breakthrough Research on Cellular Wellness

    The updated edition of the New York Times bestseller from the chair of the Nu Skin Scientific Advisory Board reveals latest science behind measurable biology and evidence-based longevity Nu Skin Enterprises Inc. (NYSE:NUS) today announced the relaunch of "The Aging Myth: Unlocking the Mysteries of Looking and Feeling Young," the updated edition of the bestselling book from Dr. Joseph Chang, chair of Nu Skin's Scientific Advisory Board. The relaunch marks a significant milestone in the evolution of evidence-based beauty and wellness, bringing together decades of research that underpin Nu Skin's science-led innovations — from ageLOC® technology to the company's intelligent beauty and wellne

    2/6/26 1:56:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises to Announce Fourth Quarter and Full Year 2025 Financial Results

    Nu Skin Enterprises Inc. (NYSE:NUS) today announced it will release fourth quarter and full year 2025 results after the market closes on Thursday, Feb. 12. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, Feb. 26. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (

    1/14/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises to Discuss Company Strategy and Opportunities at ICR Conference

    Nu Skin Enterprises Inc. (NYSE:NUS) today announced president and CEO Ryan Napierski will participate in a moderated fireside chat to discuss company strategy and the state of the business on Monday, Jan. 12. The discussion will include the company's plans in 2026 for launching its Prysm iO intelligent wellness device and future opportunities in emerging markets, including India. The company's fireside chat will be webcast live beginning at 1:30 p.m. ET. Those wishing to access the event can visit the Nu Skin investor relations page at ir.nuskin.com. The archive of the webcast will be available at this same location through Monday, Jan. 26. About Nu Skin Enterprises Inc. The Nu Skin E

    1/9/26 7:00:00 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    SEC Filings

    View All

    SEC Form 10-Q filed by Nu Skin Enterprises Inc.

    10-Q - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    11/6/25 6:29:08 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    11/6/25 4:26:05 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    SEC Form 144 filed by Nu Skin Enterprises Inc.

    144 - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    9/3/25 2:56:58 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Product Officer Hatchett Steven Keith bought $52,855 worth of shares (5,500 units at $9.61), increasing direct ownership by 3% to 167,565 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    11/12/25 4:32:45 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Chief Product Officer Hatchett Steven Keith bought $49,010 worth of shares (6,500 units at $7.54), increasing direct ownership by 4% to 162,065 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    5/28/25 6:26:44 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nu Skin downgraded by Jefferies with a new price target

    Jefferies downgraded Nu Skin from Buy to Hold and set a new price target of $39.00 from $43.00 previously

    1/31/23 6:17:27 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    DA Davidson reiterated coverage on Nu Skin Enterprises with a new price target

    DA Davidson reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $50.00 from $47.00 previously

    2/17/22 4:46:52 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Citigroup reiterated coverage on Nu Skin Enterprises with a new price target

    Citigroup reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $49.00 from $43.00 previously

    11/24/21 11:03:39 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/12/24 4:47:17 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/6/24 10:20:59 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/4/24 10:21:31 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Leadership Updates

    Live Leadership Updates

    View All

    Nu Skin Enterprises Appoints James Winett to Board of Directors

    Nu Skin Enterprises (US:NYSE) today announced the appointment of James Winett, a managing member of SIZE Advisory Group, to the company's board of directors. He was elected by shareholders at the annual shareholder meeting for Nu Skin Enterprises. "Jim adds extensive expertise in strategic planning, operations and finance from his many years of consulting experience," said Steven J. Lund, executive chairman of the board. "He will also be an asset to our Rhyz businesses with his background in corporate transactions and advising small businesses and start-ups. We welcome Jim to the board and look forward to tapping into his insights and experience." Winett is a managing member of SIZE Adv

    6/2/25 12:19:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Appoints Mark A. Zorko to Board of Directors

    Nu Skin Enterprises (NYSE:NUS) today announced the appointment of Mark A. Zorko, a principal with executive management association Brentwood Advisory Group, to the company's board of directors. The board also appointed Zorko to serve on its audit committee and the nominating and corporate governance committee. "Mark brings extensive C-level leadership experience with several global public companies, as well as more than 20 years of board-level experience," said Steven J. Lund, executive chairman of the board. "We welcome Mark to the board and look forward to leveraging his extensive business insights and experience." Zorko is a principal with Brentwood Advisory, an association he co-found

    9/12/24 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

    9/6/24 6:43:00 PM ET
    $AAL
    $ADMA
    $ADNT
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NUS
    Financials

    Live finance-specific insights

    View All

    Nu Skin Enterprises to Announce Fourth Quarter and Full Year 2025 Financial Results

    Nu Skin Enterprises Inc. (NYSE:NUS) today announced it will release fourth quarter and full year 2025 results after the market closes on Thursday, Feb. 12. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, Feb. 26. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (

    1/14/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Reports Third Quarter Earnings

    Company preparing for limited introduction of Prysm iO and pre-market opening of India in the fourth quarter Nu Skin Enterprises Inc. (NYSE:NUS) today announced third quarter revenue and earnings per share within its guidance range. Executive Summary Q3 2025 vs. Prior-year Quarter Revenue $364.2 million; (15.3)% or (11.5)% excluding Mavely 2024 revenue (0.4)% FX impact or $(1.7) million Earnings Per Share (EPS) $0.34 compared to $0.17 Customers 746,256; (10)% Paid Affiliates 130,096; (13)% Sales Leaders 31,150; (19)% "We are pleased with our third quarter results, which were in line with expectations, as we continue to navigate a challenging m

    11/6/25 4:06:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Announces Quarterly Dividend

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on Dec. 10, 2025, to shareholders of record on Nov. 28, 2025. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-a

    11/6/25 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care